Get the Stockscreener App
301.37
0.72%
-2.19
After Hours:
296.48
-4.89
-1.62%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $301.37, with a volume of 1.55M.
It is down -0.72% in the last 24 hours and up +7.94% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$303.56
Open:
$304.33
24h Volume:
1.55M
Relative Volume:
0.60
Market Cap:
$162.05B
Revenue:
$34.13B
Net Income/Loss:
$5.93B
P/E Ratio:
27.50
EPS:
10.96
Net Cash Flow:
$10.92B
1W Performance:
-2.54%
1M Performance:
+7.94%
6M Performance:
+6.11%
1Y Performance:
-9.57%
1-Day Range:
$299.66
$305.57
1-Week Range:
$297.78
$311.28
52-Week Range:
$253.30
$340.89
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
301.37 | 163.23B | 34.13B | 5.93B | 10.92B | 10.96 |
|
LLY
Lilly Eli Co
|
760.08 | 684.93B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.26 | 404.87B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
189.31 | 337.77B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
116.63 | 226.92B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
81.75 | 207.49B | 63.62B | 16.41B | 17.04B | 6.49 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Biotechnology Market is evolving rapidly Through 2025 To 2032 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? - TradingView
Harvest Fund Management Co. Ltd Raises Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Rises 0.75 Despite 27.65% Volume Drop to 430M 272nd in Market as Golden Cross and Earnings Outlook Fuel Optimism - AInvest
Viridian inks Japan licensing deal as it seeks to take on Amgen's Tepezza next year - Endpoints News
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Valley Wealth Managers Inc. Has $27.15 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Applied Finance Capital Management LLC Increases Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Assetmark Inc. Sells 118,002 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by First Heartland Consultants Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Bought by HB Wealth Management LLC - MarketBeat
Brookwood Investment Group LLC Acquires Shares of 1,298 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Unlocking the Potential of Bispecific Antibodies: A Deep Dive into Akeso, Amgen, and Roche's Strategic Play in a $16.8B Market by 2035 - AInvest
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Federated Hermes Inc. Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen (AMGN) to Release Earnings on Tuesday - MarketBeat
Meeder Advisory Services Inc. Boosts Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Meeder Asset Management Inc. Has $11.26 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
ARK Investment Management LLC Trims Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Marco Investment Management LLC Purchases 2,501 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Foundations Investment Advisors LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mackenzie Financial Corp Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Atria Investments Inc Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zanubrutinib Market Growth Expected to See Next Level with Amgen - openPR.com
Zurcher Kantonalbank Zurich Cantonalbank Has $166.72 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
TD Asset Management Inc Has $153.27 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Cetera Investment Advisers Buys 26,309 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Avantax Advisory Services Inc. Acquires 6,266 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Advisor OS LLC Has $1.56 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Lifeworks Advisors LLC Sells 16,173 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Stewart’s Denial of Institution on Two Amgen IPRs Highlights Possible Tension Between Drug Pricing, USPTO Priorities - IPWatchdog.com
Brokerages Set Amgen Inc. (NASDAQ:AMGN) Target Price at $307.27 - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Neo Ivy Capital Management - MarketBeat
Amgen’s Promising Study on AMG 732 for Thyroid Eye Disease: A Potential Game-Changer - TipRanks
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Oncology Biosimilars Market Set to Witness Significant Growth by 2025-2032 | Amgen Inc., Allergan, Plc, Mylan N.V. - openPR.com
828 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Fielder Capital Group LLC - MarketBeat
Kinsale Capital Group Inc. Grows Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
TCW Group Inc. Sells 1,018 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Purkiss Capital Advisors LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mitchell Sinkler & Starr PA Sells 1,750 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Woodard & Co. Asset Management Group Inc. ADV - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by LPL Financial LLC - MarketBeat
Navellier & Associates Inc. Trims Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Principle Wealth Partners LLC Lowers Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
BofA Reiterates a Sell Rating on Amgen (AMGN) - Insider Monkey
BMO Cuts Amgen (AMGN) Price Target After Mixed MariTide Data at ADA Conference - MSN
Is Amgen Inc. a growth stock or a value stockUnlock real-time stock alerts for quick profits - jammulinksnews.com
Carnegie Investment Counsel Sells 2,996 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
What catalysts could drive Amgen Inc. stock higher in 2025Invest confidently with professional market insights - jammulinksnews.com
Rep. Jefferson Shreve Sells Off Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):